AbbVie (ABBV) Dividend History

• Pays: quarterly — 55 dividends in our record since January 2013, when AbbVie spun off from Abbott Laboratories.
• The streak: annual payouts have risen every full year of the company's existence — 12 consecutive rising years in our data.
• The growth: from $0.40 per quarter at the 2013 spin-off to $1.73 today — the payout has multiplied more than fourfold in thirteen years.
• Current rate: $1.73 per quarter — $6.83 over the trailing twelve months, about 2.6% of the recent ~$265.79 price.
• The engine risk: pharma dividends ride patent cycles — AbbVie grew this payout through the loss of Humira, once the world's best-selling drug, on the strength of its successors.

AbbVie inherited Abbott's dividend culture (Abbott is itself a long-streak payer) and has out-raised nearly every large-cap payer since: better than 4x growth in 13 years. The record's real test came when Humira — once the world's top-selling drug — lost exclusivity, and the raises continued through it. Patent cliffs are pharma's permanent weather; so far this payout has grown through every one.

Each point is one ABBV dividend since January 2013 — a short record by blue-chip standards, and the steepest climb of any large payer we chart.

Loading the latest data…

Each point is one payment; the line ends at the most recent payout. The table below totals them by year.

• Trailing 12 months: $6.83 per share across 4 payments — up 6% from $6.47 in the 12 months before. What a change like that does to your income →
• Current pace: recent payments annualize to $6.56 — 4% below the trailing figure. When those two disagree, the trailing yield is quoting the past. Live cut & raise board →
• Share price, same 12 months: up 22% (dividends excluded) — income and principal are one story. Erosion Index →
• Record: 55 payments over 14 years; the largest single payment was $1.73 (Jan 2026).
• Payment drops ≥20% below trend, last 24 months: none. Get one short email if that changes →

Every figure above is computed from ABBV's actual payment record and share-price history as of the date shown — not copied from a fact sheet. Recomputed regularly; the chart above always shows the live data.

Writing about ABBV? Drop this live card into your blog, newsletter, or forum post. It redraws itself with fresh payment data on every view — no stale screenshots. Free to use with the link included.

Click the code to select it, then copy. Updates hourly. All 169 tickers, iframe & Markdown versions →

"Next expected" is estimated from ABBV's recent payment rhythm — the fund announces exact dates shortly before each payout, and the data feed can lag a few days. You must own shares before the ex-dividend date to receive that payout; the cash typically arrives days later. See every fund's upcoming date on the live dividend calendar.

A real total-return estimate, assuming every payout was reinvested — including what happened to the share price. Before taxes and fees. Past performance does not predict the future.

AbbVie's first independent dividend in 2013 was $0.40 a quarter; today's is $1.73. No other mega-cap payer we chart grew its check that fast — and the growth continued straight through losing U.S. exclusivity on Humira, the frankest possible stress test of a pharma dividend. The trailing year paid $6.83 per share, about 2.6% on the recent $265.79 price: a genuine middle path between JNJ's 1.4% safety and the double-digit engineered yields.

Compare it with JNJ for the two pharma income philosophies — dynasty streak versus growth rate — or with PFE, whose higher yield prices in exactly the patent-cliff fears ABBV has so far outrun. Both overlays are one click on the compare tool.

Data source: Yahoo Finance. Figures are per share; the current year may be partial and figures should be verified against official sources.

Calculated from complete calendar years in the data above. Past results don't guarantee future payments.